Overview
Mermaid diagram (expand to render)
Asterias Biotherapy was a biotechnology company focused on developing novel cell therapies for serious diseases, particularly in regenerative medicine and immunotherapy. The company leveraged stem cell technology and novel immunotherapy approaches to address unmet medical needs in oncology, spinal cord injury, and degenerative diseases.
The company was founded in 2009 as a subsidiary of [Geron Corporation](/companies/geron-corporation), one of the pioneering companies in human embryonic stem cell (hESC) research. Asterias was acquired by [Lineage Cell Therapeutics](/companies/lineage-cell-therapeutics) in 2019, combining the cell therapy platforms of both companies["@lineagedeal"][@lineage].
Note: Asterias is no longer an independent operating company following its acquisition. The company's programs are now continued through Lineage Cell Therapeutics.
Company History
Origins with Geron Corporation (2009-2011)
Asterias Biotherapy was founded in 2009 as a subsidiary of Geron Corporation, a company that had been at the forefront of stem cell research since the 1990s. Geron had established significant intellectual property and expertise in hESC research, and created Asterias as a vehicle to advance cell therapy programs into clinical development[@geron].
The creation of Asterias was part of Geron's strategic decision to spin out its cell therapy programs into a dedicated subsidiary, allowing for focused development and potentially separate funding. This structure enabled specialized management and dedicated resources for the cell therapy pipeline.
Independent Operations (2011-2019)
In 2011, Asterias became an independent, publicly traded company (NYSE: AST). During this period, the company:
- Advanced its stem cell programs toward clinical development
- Established manufacturing capabilities for cell therapy products
- Built a team of experts in cell biology, manufacturing, and clinical development
- Filed and received FDA clearance for clinical trials involving hESC-derived cells
Acquisition by Lineage Cell Therapeutics (2019)
In 2019, Asterias was acquired by Lineage Cell Therapeutics, another cell therapy company with complementary programs. The acquisition combined:
- Asterias's hESC-derived cell therapy programs
- Lineage's OPC (oligodendrocyte progenitor cell) technology
- Combined manufacturing capabilities and clinical expertise
The combined company continued development of both Asterias and Lineage programs under the Lineage Cell Therapeutics name[@lineage][@lineagedeal].
Company Overview
| Attribute | Details |
|-----------|---------|
| Headquarters | Menlo Park, California, USA |
| Founded | 2009 (as Geron subsidiary) |
| Became Independent | 2011 |
| Acquired by | Lineage Cell Therapeutics (2019) |
| Focus | Cell therapy, Regenerative medicine, Immunotherapy |
| Stock Symbol | AST (former) |
Asterias developed several technology platforms for cell therapy development:
The company utilized hESCs as the foundation for its regenerative medicine programs. hESCs possess the capacity to differentiate into any cell type in the human body, making them ideal for cell replacement therapies.
Manufacturing Capabilities
- Scalable hESC culture systems
- Defined differentiation protocols for specific cell types
- Banking and quality control systems
- GMP-compliant manufacturing processes
Key Differentiated Cell Types
- Oligodendrocyte progenitor cells (OPCs): For demyelination and spinal cord injury
- Pancreatic beta cells: For diabetes treatment
- Neural precursor cells: For neurological disorders
- Cartilage cells: For orthopedic applications[@hesc-research]
Asterias also developed immunotherapy approaches, primarily focused on cancer treatment:
CAR-T Cell Therapy
The company developed chimeric antigen receptor T-cell (CAR-T) therapies targeting various cancer antigens. These engineered T-cells were designed to recognize and destroy cancer cells.
- AST-VAC1: Autologous dendritic cell vaccine
- AST-VAC2: Allogeneic tumor cell vaccine
These approaches leveraged the immune system to target cancer cells through different mechanisms[@cart-therapy].
Pipeline Programs
AST-OPC1: Spinal Cord Injury Program
AST-OPC1 was Asterias's most advanced program, involving oligodendrocyte progenitor cells (OPCs) derived from hESCs for treatment of spinal cord injury.
Mechanism of Action
The therapy aimed to restore function by:
- Cell replacement: Transplanted OPCs can differentiate into oligodendrocytes, the cells responsible for producing myelin in the central nervous system
- Remyelination: New oligodendrocytes can remyelinate denuded axons, restoring nerve conduction
- Neuroprotection: Secretion of growth factors supporting existing neurons
- Axonal regeneration: Creating a permissive environment for axon growth
Clinical Development
- Phase 1 Trial: First-in-human study in patients with complete thoracic spinal cord injury
- Dosing: Multiple dose escalation cohorts
- Endpoints: Safety, neurological function assessment using International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
The trial demonstrated preliminary evidence of safety and potential efficacy, making it one of the first hESC-derived cell therapies to reach clinical testing[@spinal-cord-injury][@oligodendrocyte].
AST-VAC1: Cancer Immunotherapy
AST-VAC1 was an autologous dendritic cell vaccine programmed with tumor antigen RNA. The therapy aimed to stimulate anti-tumor immune responses in cancer patients.
Mechanism
- Patient's dendritic cells are collected and exposed to tumor-associated antigen RNA
- Activated dendritic cells are reintroduced to stimulate T-cell responses
- Designed to target specific tumor antigens
Clinical Development
- Evaluated in multiple oncology indications
- Advanced through Phase 1 and Phase 2 clinical trials
- Demonstrated evidence of immune activation in some patients
CAR-T Cell Programs
Asterias developed several CAR-T therapy programs targeting different cancers:
| Program | Target | Indication | Development Status |
|---------|--------|------------|-------------------|
| AST-CD19 | CD19 | B-cell malignancies | Preclinical |
| AST-CD20 | CD20 | B-cell lymphoma | Preclinical |
| AST-CD123 | CD123 | Acute myeloid leukemia | Preclinical |
These programs utilized next-generation CAR constructs with:
- Enhanced persistence
- Reduced tonic signaling
- Safety switches
- Multiple signaling domains[@cart-therapy]
Diabetes Program
Asterias maintained a preclinical program for pancreatic beta cell replacement:
- Approach: hESC-derived insulin-producing beta cells
- Indication: Type 1 diabetes
- Goal: Restore endogenous insulin production
- Status: Research and preclinical development
Notable Achievements
First FDA Clearance for hESC Clinical Trial
Asterias achieved a significant regulatory milestone as the first company to receive FDA clearance for a clinical trial involving hESC-derived cells. This achievement required:
- Extensive preclinical toxicology and safety studies
- Development of GMP-compliant manufacturing processes
- Detailed characterization of the cell product
- Rigorous review of clinical trial protocols
Manufacturing Excellence
The company developed robust manufacturing processes for cell therapy products:
- Scalable cell culture systems
- Cryopreservation protocols for cell banks
- Quality control assays for identity, purity, and potency
- GMP-compliant facility operations
Academic Partnerships
Asterias established partnerships with leading academic institutions:
- University of California system
- [Stanford University](/institutions/stanford)
- [Johns Hopkins University](/institutions/johns-hopkins-university)
- Multiple international research centers
Research Contributions
Asterias's research contributed to the advancement of cell therapy in several areas:
Stem Cell Biology
- Differentiation protocols for generating specific cell types
- Characterization methods for stem cell-derived products
- Understanding of cell therapy mechanisms
Clinical Cell Therapy
- Clinical trial design for cell-based therapies
- Outcome measures for neurological injury trials
- Regulatory pathway development
Manufacturing
- Scalable cell production methods
- Quality control approaches
- Shipping and storage protocols
Pipeline at Acquisition
When Asterias was acquired by Lineage Cell Therapeutics in 2019, the combined pipeline included:
| Program | Indication | Development Stage |
|---------|------------|-------------------|
| AST-OPC1 | Spinal cord injury | Phase 1 complete |
| AST-VAC1 | Cancer immunotherapy | Phase 2 |
| AST-VAC2 | Cancer immunotherapy | Phase 1 |
| CAR-T CD19 | B-cell lymphoma | Preclinical |
| CAR-T CD20 | B-cell lymphoma | Preclinical |
| Beta cells | Type 1 diabetes | Preclinical |
Legacy and Impact
Although Asterias no longer exists as an independent company, its legacy includes:
Regulatory Pioneering: First FDA clearance for hESC-derived cell therapy clinical trial
Scientific Contributions: Published research on stem cell differentiation and cell therapy
Manufacturing Innovation: Developed scalable cell therapy manufacturing processes
Talent Development: Trained a generation of cell therapy scientists and manufacturing expertsCurrent Status
Following the acquisition, Lineage Cell Therapeutics continues to advance the programs originally developed by Asterias:
Current Pipeline (Lineage)
- OPC1 (formerly AST-OPC1): Continued development for spinal cord injury
- VAC programs: Continued cancer immunotherapy development
- New programs: Additional cell therapy indications
Manufacturing
The acquired manufacturing facilities continue to operate, producing cell therapy products for clinical trials.
See Also
- [Cell Therapy](/mechanisms/cell-therapy)
- [Stem Cell Therapy](/therapeutics/stem-cell-therapy)
- [Regenerative Medicine](/mechanisms/regenerative-medicine)
- [CAR-T Cell Therapy](/therapeutics/car-t-cell-therapy)
- [Spinal Cord Injury](/diseases/spinal-cord-injury)
- [Lineage Cell Therapeutics](/companies/lineage-cell-therapeutics)
- [Geron Corporation](/companies/geron-corporation)
External Links
- [Lineage Cell Therapeutics](https://lineagecell.com)
- [Lineage Cell Therapeutics Pipeline](https://lineagecell.com/pipeline/)
- [Asterias Clinical Trials](https://clinicaltrials.gov/ct2/results?cond=&term=Asterias+Biotherapy)
- [PubMed - Stem Cell Therapy](https://pubmed.ncbi.nlm.nih.gov/?term=stem+cell+therapy)
- [PubMed - Spinal Cord Injury Cell Therapy](https://pubmed.ncbi.nlm.nih.gov/?term=spinal+cord+injury+cell+therapy)
- [PubMed - CAR-T Cell Therapy](https://pubmed.ncbi.nlm.nih.gov/?term=CAR-T+cell+therapy)
References
[Lineage Cell Therapeutics - Asterias Programs](https://lineagecell.com/pipeline/)
[Asterias Clinical Trials](https://clinicaltrials.gov/ct2/results?cond=&term=Asterias+Biotherapy)
[Geron Corporation - Stem Cell History](https://www.geron.com/)
[Human Embryonic Stem Cell Research and Applications (2020)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Cell Therapy for Spinal Cord Injury (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Oligodendrocyte Progenitor Cells for Demyelination (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[CAR-T Cell Therapy for Cancer (2019)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Lineage Cell Therapeutics Acquires Asterias (2019)](https://lineagecell.com/press-releases/)Pathway Diagram
The following diagram shows the key molecular relationships involving Asterias Biotherapy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)